Welcome to Snoretox Ltd.
Inventing a drug to resolve BOAS (Brachycephalic Obstructive Airways Syndrome) along with human muscle weakness conditions.
Snoretox has been selected to present at two of the world’s most prestigious veterinary conferences: the ACVIM Forum (Seattle, June 2026) and the ECVS Annual Scientific Meeting (Liverpool, July 2026).
These internationally recognised meetings bring together leading veterinary specialists and represent the highest standards of clinical and scientific excellence. Acceptance is competitive and reflects the quality and growing relevance of Snoretox’s work. Presenting at both forums marks an important milestone for the company and highlights its increasing recognition within the global veterinary community.
Snoretox Wins the 2025 Innovation Award at the Animal Health Summit in Kansas City!
Spontaneous media reporting of one of our trial participants:
Courtesy of the Herald Sun
Article by Anna Shreeves (photo by Jason Edwards)
Breathing easier? Snore thing!
You’ve heard of Botox but it’s time to be introduced to Snoretox, a potentially life-changing drug for dogs that struggle to breathe properly.
This seven-year-old pug, Pugtato, has brachycephalic obstructive airway syndrome, an affliction that often affects the breed.
For many of these flat-faced dogs, there has been no way to remedy their breathing, until now.
A clinical trial led by Dr Arthur House at Peninsula Vet Emergency & Referral Hospital with RMIT University chose Pugtato as its test subject.
Following some preliminary tests, the pug received two injections of Snoretox. Two months on, the effects are said to be remarkable.
Joanna Herceg, Pugtato’s owner and founder of Pug Rescue Victoria, said his improvement had been “overwhelmingly drastic.”
Before Snoretox, he was an “agitated” dog that would struggle to settle. Now, she can barely recognise him. His energy has increased, he is breathing well and he seems like an all-round contented dog.
“I will try to do everything for these dogs, and it’s heartbreaking to watch them suffer from not being able to breathe properly,” Ms Herceg said.
“He has gone from an unadoptable dog to a really awesome adoptable dog.”
pugrescue.org.au
Our timeline to success
2025
2024
2022
Snoretox was today singled out in the announcement $100 million for the Breakthrough Victoria – University Innovation Platform.
‘Snoretox is another example of a company commercialising RMIT-developed technology – a novel muscle toning toxin-based therapeutic for treating sleep apnea and snoring, as well as a range of other weak muscle conditions such as incontinence.’
2021
Snoretox wins a Medical Research Future Fund (MRFF) 2021 Frontier Health and Medical Research Initiative Grant, securing a $1 million grant.
The MRFF is a 20 Billion dollar fund set up by the Australian Federal Government to promote medical research and it’s translation to the clinic.
2020
2020
First Scientific Publication: Molecular Immunology. Volume 127. November 2020
In the laboratories of RMIT University, in Melbourne, Australia, we have invented and patented the world’s first effective and long-lasting drug for muscle weakness.
Our game-changing technology is based on molecules of tetanus toxin, modified to ensure they work around the tetanus vaccine.
Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of tetanus toxin to achieve the opposite effect – muscle toning.
Snoretox dogs are happy dogs!
Novel modified tetanus toxin muscle toning biotherapeutics for:
- BOAS
- Sleep apnoea and snoring
- Muscle recovery
- Sphincter weakness (anal, bladder, pelvic floor)
- Neurological (Multiple Sclerosis, Motor Neuron Disease, Myopathy)
- Veterinary (sleep apnoea, “roaring” larynx disorders, sphincter incontinence, muscle weakness)
- Cosmetic muscle toning (eyelid issues such as ectropion and ptosis, facial and chin lifting, general muscle toning)
Our therapeutics are trademarked SnoretoxTM (for sleep apnoea) and TonetoxTM (for other applications).
